过氧化物酶体增殖物激活受体家族参与溃疡性结肠炎患者的治疗反应和轻度临床病程。

Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis.

作者信息

Yamamoto-Furusho J K, Jacintez-Cazares M, Furuzawa-Carballeda J, Fonseca-Camarillo G

机构信息

Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Vasco de Quiroga No. 15, Colonia Sección XVI, 14000 Mexico City, Mexico.

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Vasco de Quiroga No. 15, Colonia Sección XVI, 14000 Mexico City, Mexico.

出版信息

Dis Markers. 2014;2014:932530. doi: 10.1155/2014/932530. Epub 2014 Dec 8.

BACKGROUND

PPARs play an important role in the regulation of intestinal inflammation.

METHODS

We included a total of 46 UC patients and 31 controls. The gene expression of PPARs was measured by RT-PCR and protein expression by immunohistochemistry.

RESULTS

PPARα gene expression was significantly decreased in patients with active UC compared with remission UC group (P = 0.001) and controls (P = 0.001). We found that low gene expression of PPARα in mucosa confers a higher risk of UC activity (P ≤ 0.0001, OR = 22.6). We observed an increase of PPARα expression in patients with UC who were treated with 5-aminosalicylates compared with those who received any other combined therapy (P = 0.03, OR = 0.08). PPARγ gene expression was decreased in the active UC group compared with UC in remission (P = 0.001) and control group (P = 0.001). An increased expression of PPARγ gene was associated with mild clinical course of the disease (P ≤ 0.001, OR = 0.05). No gene expression of PPARβ/δ was found in the colonic mucosa from UC patients and controls.

CONCLUSION

Our results suggest that patients with high gene expression of PPARs have a better response to medical treatment and a mild clinical course of the disease.

背景

过氧化物酶体增殖物激活受体（PPARs）在肠道炎症调节中起重要作用。

方法

我们共纳入46例溃疡性结肠炎（UC）患者和31例对照。通过逆转录聚合酶链反应（RT-PCR）检测PPARs的基因表达，通过免疫组织化学检测蛋白表达。

结果

与缓解期UC组（P = 0.001）和对照组（P = 0.001）相比，活动期UC患者的PPARα基因表达显著降低。我们发现黏膜中PPARα基因低表达赋予UC活动更高风险（P≤0.0001，比值比[OR]=22.6）。我们观察到，与接受任何其他联合治疗的UC患者相比，接受5-氨基水杨酸治疗的UC患者PPARα表达增加（P = 0.03，OR = 0.08）。与缓解期UC（P = 0.001）和对照组（P = 0.001）相比，活动期UC组的PPARγ基因表达降低。PPARγ基因表达增加与疾病的轻度临床病程相关（P≤0.001，OR = 0.05）。在UC患者和对照的结肠黏膜中未发现PPARβ/δ的基因表达。